Justin Call
About
Justin Call is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology.
According to data from OpenAlex, Justin Call has authored 34 papers receiving a total of 343 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 10 papers in Radiology, Nuclear Medicine and Imaging and 8 papers in Molecular Biology. Recurrent topics in Justin Call's work include CAR-T cell therapy research (9 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Justin Call is often cited by papers focused on CAR-T cell therapy research (9 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Justin Call collaborates with scholars based in United States, Spain and France. Justin Call's co-authors include D. Ross Camidge, Sabine Eckhardt, Li Zhou, M. S. Wertheim, Carolina Escobar, Fitzroy W. Dawkins, Andres Forero‐Torres, William J. Edenfield, Martin Gutierrez and Tycel Phillips and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
In The Last Decade
Justin Call
33 papers receiving 335 citations
Peers
Justin Call
Savita Bhalla United States
Aditi Sharma United States
Tamer Zeren United States
Jennifer Mahoney United States
Yunfeng Shen China
Hong-Xia Qiu China
Young-Soon Na South Korea
Suk-Young Yoo United States
Yolla Haibe Lebanon
Citations per year, relative to Justin Call Justin Call (= 1×)
peers
Savita Bhalla
Countries citing papers authored by Justin Call
Since
Specialization
Citations
This map shows the geographic impact of Justin Call's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Justin Call with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Justin Call more than expected).
Fields of papers citing papers by Justin Call
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Justin Call. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Justin Call. The network helps show where Justin Call may publish in the future.
Co-authorship network of co-authors of Justin Call
This figure shows the co-authorship network connecting the top 25 collaborators of Justin Call. A scholar is included among the top collaborators of Justin Call based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Justin Call. Justin Call is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Gao, Xin, Amita Patnaik, Nehal J. Lakhani, et al.. (2025). NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors.. Journal of Clinical Oncology. 43(5_suppl).
2.
Winer, Ira, Noelle Cloven, Debra L. Richardson, et al.. (2025). Rinatabart sesutecan (Rina-S) for patients with advanced endometrial cancer: First disclosure from dose expansion cohort B2 of the GTC1184-01 study.. Journal of Clinical Oncology. 43(16_suppl). 3039–3039.
3.
Lakhani, Nehal J., Daphne Stewart, Debra L. Richardson, et al.. (2025). First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer. Journal for ImmunoTherapy of Cancer. 13(1). e010565–e010565.
4.
Fakih, Marwan, Davendra Sohal, Justin Call, et al.. (2024). 625P Initial results from the phase I, first-in-human study of the covalent, PI3Kα inhibitor TOS-358 in patients with solid tumors, expressing PI3Kα mutations or amplifications. Annals of Oncology. 35. S499–S500.
5.
Sonpavde, Guru, Justin Call, Gerald S. Falchook, et al.. (2024). A first-in-human (FIH), phase 1/2, dose-escalation, dose-optimization, and dose-expansion study of PARP1-selective inhibitor IMP1734 in participants with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS3191–TPS3191.
6.
Piha‐Paul, Sarina A., Justin Call, Alexander I. Spira, et al.. (2024). Recommended phase 2 dose (RP2D) of nemvaleukin alfa in patients (pts) with advanced solid tumors treated with less frequent intravenous (IV) dosing (ARTISTRY-3).. Journal of Clinical Oncology. 42(16_suppl). 2587–2587.
7.
Patnaik, Amita, Nilofer S. Azad, Mitesh J. Borad, et al.. (2024). An open-label phase 1 study to investigate SGNCEACAM5C/SAR445953 in adults with advanced solid tumors (SGNCEA5C-001).. Journal of Clinical Oncology. 42(16_suppl). TPS3160–TPS3160.
8.
Park, Jong Chul, David Berz, Manish Sharma, et al.. (2023). 742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors. SHILAP Revista de lepidopterología. A836–A837.
9.
Bossi, Paolo, Irene Braña, Víctor Moreno, et al.. (2023). 362P Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in head and neck squamous cell cancer (HNSCC). Annals of Oncology. 34. S1610–S1611.
10.
Perez, Cesar A., Jason T. Henry, Nehal J. Lakhani, et al.. (2023). 660MO First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: Preliminary results of a phase I study (SGNB7H4V-001). Annals of Oncology. 34. S464–S465.
11.
McKean, Meredith, Ecaterina E. Dumbrava, Omid Hamid, et al.. (2023). 1021MO Safety and efficacy of etigilimab (anti-TIGIT) with nivolumab (anti-PD1) in recurrent/advanced solid tumors. Annals of Oncology. 34. S621–S622.
12.
Call, Justin, Ian Anderson, Debra L. Richardson, et al.. (2023). Abstract CT244: Phase 1/2 study of PRO1184, a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors. Cancer Research. 83(8_Supplement). CT244–CT244.
13.
Call, Justin, Douglas Orr, Debra L. Richardson, et al.. (2023). Phase 1/2 study of PRO1184, a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors.. Journal of Clinical Oncology. 41(16_suppl). TPS3157–TPS3157.
14.
Sen, Shiraj, Justin Call, Kyriakos P. Papadopoulos, F. Donelson Smith, & Edward H. van der Horst. (2023). 1532 A phase 1/2 study of safety, tolerability, and pharmacokinetics of SNS-101, a pH-sensitive anti-VISTA mAb, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors. SHILAP Revista de lepidopterología. A1755–A1755.
15.
Ammakkanavar, Natraj Reddy, Justin Call, Toshio Shimizu, et al.. (2022). Abstract CT202: A first-in-human phase 1 study of LY3537982, a novel, highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C mutant advanced solid tumors (trial in progress). Cancer Research. 82(12_Supplement). CT202–CT202.
16.
McKean, Meredith, Ecaterina E. Dumbrava, Omid Hamid, et al.. (2022). Safety and efficacy of etigilimab in combination with nivolumab in select recurrent/advanced solid tumors.. Journal of Clinical Oncology. 40(16_suppl). 2651–2651.
17.
Harb, Wael A., Melissa L. Johnson, Jonathan W. Goldman, et al.. (2017). A phase 1b/2 study of ARRY-382, an oral inhibitor of colony stimulating factor 1 receptor (CSF1R), in combination with pembrolizumab (Pembro) for the treatment of patients (Pts) with advanced solid tumors.. Journal of Clinical Oncology. 35(15_suppl). TPS3110–TPS3110.
18.
Call, Justin, Sabine Eckhardt, & D. Ross Camidge. (2008). Targeted manipulation of apoptosis in cancer treatment. The Lancet Oncology. 9(10). 1002–1011.
19.
Jonker, Derek J., Scott A. Laurie, Justin Call, et al.. (2008). Sunitinib (SU) in combination with pemetrexed (P) in patients (pts) with advanced solid malignancies: A phase I dose escalation study. Journal of Clinical Oncology. 26(15_suppl). 3566–3566.
20.
O’Bryant, Cindy L., Stephen Leong, D. Ross Camidge, et al.. (2007). A phase 1 study of belinostat (PXD101) in combination with bortezomib in patients with advanced solid tumors and lymphoma. Molecular Cancer Therapeutics. 6.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Savita Bhalla Breakdown of academic impact, for papers by Aditi Sharma Breakdown of academic impact, for papers by Tamer Zeren Breakdown of academic impact, for papers by Jennifer Mahoney Breakdown of academic impact, for papers by Yunfeng Shen Breakdown of academic impact, for papers by Hong-Xia Qiu Breakdown of academic impact, for papers by Young-Soon Na Breakdown of academic impact, for papers by Suk-Young Yoo Breakdown of academic impact, for papers by Yolla Haibe